scorecardresearch
Follow Us:
Saturday, July 02, 2022

Eli Lilly’s antibody combination receives FDA emergency use authorization for Covid-19

Lilly's combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in Covid-19 patients by 70 per cent, data from a late-stage trial showed in January.

By: Reuters |
February 10, 2021 12:28:59 pm
Eli Lilly, Covid-19Eli Lilly and Co. corporate headquarters in Indianapolis. (AP Photo/Darron Cummings, File)

Eli Lilly’s combination antibody therapy to fight COVID-19 has been granted emergency use authorization by the US Food and Drug Administration, Lilly said on Tuesday.

Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in Covid-19 patients by 70 per cent, data from a late-stage trial showed in January. Lilly said the therapy will be available immediately.

“There are 100,000 doses ready immediately and an additional 150,000 doses will be available throughout the first quarter,” Lilly said in a statement.

The company said that in collaboration with Amgen, it plans to manufacture up to 1 million doses of etesevimab for administration with bamlanivimab by mid-2021. Lilly said the “therapy is authorized for the treatment of mild to moderate Covid-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Best of Express Premium
UPSC Essentials: Weekly news express — PGII to POEMPremium
Women’s emancipation or population control? Why abortion was legalised in...Premium
Udaipur killing on video | ‘Do something spectacular’: Man from Pak told ...Premium
In village of fauji dreams, second thoughts, insecurity over AgnipathPremium

“The FDA, separately, said bamlanivimab and etesevimab are not authorized for patients hospitalized due to Covid-19 or who require oxygen therapy due to COVID-19.”

Late last month, Lilly reported a fourth-quarter profit that topped Wall Street estimates. It recorded $871.2 million in quarterly sales of the COVID-19 therapy bamlanivimab, benefiting from the US government’s move to stock up on the drug for emergency use.

UPSC KEY Have you seen our section dedicated to helping USPC aspirants decode daily news in the context of their exams?

📣 Join our Telegram channel (The Indian Express) for the latest news and updates

For all the latest World News, download Indian Express App.

  • Newsguard
  • The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
  • Newsguard
0 Comment(s) *
* The moderation of comments is automated and not cleared manually by indianexpress.com.
Advertisement
Advertisement
Advertisement
Advertisement